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OBJECTIVE: The 13C-urea breath test is the main non-invasive test for the diagnosis of Helicobacter pylori
infection. The availability of this test throughout the country is limited, mainly due to the difficulty in obtaining
the labeled isotope from abroad. Recently, researchers from the Nuclear Energy Center in Agriculture at the
University of Sa˜o Paulo (CENA/USP) succeeded in synthesizing 13C-enriched urea for Helicobacter pylori
diagnosis. The aim of the study was to compare the performance of the 13C-urea breath test using 13C-urea
acquired abroad with that of a test using 13C-urea synthesized in Brazil.
METHOD: Sixty-four dyspeptic patients participated in the study (24 men and 40 women). Initially, the patients
performed the 13C-urea breath test using the imported substrate (Euriso-Top, France). Seven to fourteen days
later, all the patients repeated the test using the Brazilian substrate. The samples from both examinations were
processed in an infrared isotope analyzer (IRIS, Wagner Analisen Technik, Germany), and all delta over baseline
(DOB) [%] values above four were considered positive results.
RESULTS: Twenty-seven patients (42%) exhibited negative results for Helicobacter pylori infection, and thirty-
seven patients (58%) exhibited positive results when tested using the foreign substrate (gold standard). There
was a 100% concordance regarding the presence or absence of infection when the gold standard results were
compared with those obtained using the Brazilian substrate.
CONCLUSIONS: Similar performance in the diagnosis of Helicobacter pylori infection was demonstrated when
using the 13C-urea breath test with the Brazilian 13C-urea substrate and the test with the substrate produced
abroad. This validation represents an important step toward increasing the availability of the 13C-urea breath
test throughout the country, which will have a positive influence on the management of Helicobacter pylori
infection.
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’ INTRODUCTION
Helicobacter pylori (H. pylori) was first identified by Marshall
and Warren (1) in 1983 in Australia and has since been found
all over the world, in at least 50% of the world’s population.
H. pylori is the major acquired environmental factor in the
pathogenesis of a large spectrum of diseases, such as acute
and chronic gastritis, gastric and duodenal ulcers, gastric
carcinomas and mucosa-associated lymphoid tissue (MALT)
lymphomas (2).
H. pylori can be detected in the gastric mucosa by different
methods, including detection in fragments that are removed
during endoscopy (invasive tests), which can be used for
histopathological, microbiological, colorimetric (urease test)
and molecular studies, and nonendoscopic techniques (non-
invasive tests), including searching for H. pylori with breath
tests that use carbon 13-labeled urea, which are based on the
organism’s ability to produce high quantities of the urea
enzyme. The principle of the latter test is based on the ability
of H. pylori (if present in the gastric setting) to breakdown
orally absorbed 13C urea into CO2. The
13CO2 diffuses into
the blood and is excreted via the lungs; therefore, it can be
easily measured in the exhaled air using a mass or infrared
spectrometer (3). Initially described in 1987 (4), the ureaDOI: 10.6061/clinics/2018/e16-553
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breath test (UBT) is considered the most well-known, well-
standardized and widely used breath test. This test is non-
radioactive, reproducible and safe and can be performed in
children and pregnant women. Multiple studies and a meta-
analysis have demonstrated that the sensitivity and specifi-
city of this test are greater than 95% compared with the
results of serology and other diagnostic methods (5-7).
This test has been validated and performed since 1998 in
the adult population of Belo Horizonte City for initial
diagnosis of H. pylori infection and/or post-treatment asses-
sment (8). However, the use of this test throughout the
country remains unacceptably restricted to a few university
centers (8-11). One of the main barriers regarding the use of
this test is the difficulty in obtaining the labeled isotope, as
the technology for carbon separation (i.e., 13C and 12C) has
not been transferred by the countries that developed it due to
economic reasons and strategic interests. Recently, research-
ers from the Center of Nuclear Energy in Agriculture of the
University of São Paulo (CENA/USP) were able to achieve
the synthesis of urea (13CO(NH2)2) with 99%
13C atoms with
a competitive production process and a reasonable cost
compared with the international market value (12).
The aim of this study was to compare the performance of
the UBT using 13C-urea that was acquired abroad with that
of the test using 13C-urea that was synthesized in Brazil in
the same population.
’ PATIENTS AND METHODS
The study was conducted at the Breath Tests Laboratory
of the Alfa Institute of Gastroenterology at the University
Hospital of the Federal University of Minas Gerais, Belo
Horizonte, MG, Brazil.
Patients
The patients were recruited from those who were routinely
sent to undergo a UBT at the Breath Tests Laboratory for the
diagnosis of H. pylori. The patients received a full explana-
tion of the objectives of the study, and once they agreed to
participate in the study, they provided written informed
consent. For inclusion in the study, the patients must not
have used proton pump inhibitors (PPIs) in the preceding
15 days or antibiotics in the preceding 30 days because these
medications could interfere with the UBT results.
13C-urea breath test
All the participants initially underwent a UBT using
13C-urea acquired abroad (Euriso-top, France); subsequently,
they underwent another UBT using the Brazilian substrate
(CENA/USP) within 7-14 days. The technical aspects of the test
are briefly described as follows. After an overnight fast, an
initial breath sample was collected from the patients by having
them blow into a balloon to determine the basal test results.
Next, the patients were administered 75 mg of 13C-urea added
to a glass (200 ml) of pure orange juice. Thirty minutes later,
an additional collection of expired air was performed, and
the material was analyzed using an infrared analyzer (IRIS,
Wagner Analysen-Technik, Germany). The results were obtai-
ned on on a delta basis per absolute mil or as DOB ‘‘delta over
baseline’’, which indicates the change in the 13CO2/
12CO2 ratio
from the metabolic activity induced by administering the
labeled urea. DOB values above 4% were considered positive
on the UBT, as previously validated by our group (8).
Statistics
Statistical analyses were performed using descriptive
statistical techniques (tables and percentages). To compare
Figure 1 - 13C-urea breath test values from 64 patients who performed the test using 13C-urea acquired abroad and 13C-urea synthesized
in Brazil.
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the pairs of samples, we used the non-parametric Wilcoxon
signed-rank test. The analyses were conducted using Minitab
16, and the level of significance was set at po0.05.
’ RESULTS
Sixty-four dyspeptic patients completed the study (24 men
and 40 women, mean age 53 years [min. 25, max. 85]).
Overall, 27/64 (42%) patients tested negative for H. pylori,
and 37/64 (58%) of the patients tested positive according
to the UBT using the imported substrate (i.e., the gold
standard).
Comparison of the UBTs using the imported and
Brazilian 13C-urea
Figure 1 presents the results of the analyses for all 64 patients
based on the cut-off value. One hundred percent concordance
regarding positivity and negativity for infection resulted when
comparing the results based on the imported and Brazilian
substrates. A Wilcoxon test revealed that there were no sig-
nificant differences between the two methods with regard to
the differences observed between the positive and negative
results based on the Brazilian substrate, and the DOB values
based on the Brazilian substrate were not underestimated
or overestimated compared with the values based on the
imported urea (p=0.23). Table 1 presents the DOB values
obtained from infected and uninfected patients using both
tests, and Figure 2 presents a scatterplot of the 128 DOB
values obtained.
’ DISCUSSION
Our results clearly demonstrated that the 13C-urea sub-
strate synthesized by CENA/USP in Brazil could achieve the
same performance on the UBT for the diagnosis of H. pylori
infection as the substrate produced by foreign biotechnology
companies; this finding could facilitate the dissemination of
this test throughout Brazil.
The UBT is now considered the gold standard non-
invasive test for detecting the presence or absence of
H. pylori infection (5). This test is superior to serology
because the decline in antibody titers after H. pylori eradi-
cation is slow and unpredictable (13,14). Although stool
antigen tests can achieve similar sensitivity and specificity
with the use of monoclonal antibody-based ELISA, they are
considered less acceptable and practical than UBT in daily
practice (5). The UBT is particularly suitable in all clinical
conditions in which endoscopy is not strictly necessary and
for verifying the success of eradication regimens (7). More
recently, the UBT, instead of prompt endoscopy, has been
considered the main test for use in the context of test-and-
treat strategy for the management of young people with
uninvestigated dyspepsia from regions with a high H. pylori
prevalence, such as Brazil (5,15).
Table 1 - DOB values (13C-imported urea and 13C-Brazilian urea) of the positive and negative patients.
Groups
Descriptive statistics Uninfected patients (n=27) Infected patients (n=37)
13C-Imported urea 13C-Brazilian urea 13C-Imported urea 13C-Brazilian urea
Min -3.30 -2.20 6.15 6.25
Mean 0.24 0.09 19.59 18.68
Standard deviation 1.32 1.12 9.21 10.57
Max 2.65 2.70 52.05 51.65
DOB: Delta over baseline.
Figure 2 - Scatterplot of the DOB values based on imported 13C-urea vs those based on Brazilian 13C-urea.
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Unfortunately, the UBT has not yet been incorporated into
daily gastroenterological practice in Brazil, and its avail-
ability remains restricted to large cities and university centers
(8-11). To enhance the availability of this test in Brazil, num-
erous challenges must be addressed, including difficulties in
acquiring infrared spectrometers, the lack of regular reim-
bursement by health care systems, the poor familiarity of
general physicians with the UBT, and problems related to the
acquisition of 13C-urea from abroad.
This study is a preliminary report that examined the per-
formance of a small volume of 13C-urea manufactured in
Brazil for the first time. Further studies involving all ethical
and regulatory aspects related to the development of a new
drug should be performed to achieve registration with the
Brazilian Health Regulatory Agency (Anvisa) before this
test is entered into the market. The results described here
should stimulate the development of large-scale production
of 13C-urea to facilitate the broader use of the UBT, and the
subsequent technological production advances should stimu-
late a dramatic reduction in the cost of the substrate, which is
currently estimated at approximately US $15.00 per test (12).
In conclusion, the 13C-urea substrate synthesized at a
Brazilian university center exhibited a performance similar to
that of the substrate produced by a foreign company when
used in the UBT to diagnose the presence or absence of
H. pylori infection. This validation represents an important
step toward improving the availability of the UBT through-
out the country, which will positively influence the diagnosis
and therapeutic management of H. pylori infection.
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